BioTelemetry, Inc. (NASDAQ:BEAT) announced today that, effective on May 5, 2017, it received early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) with respect to its previously announced tender offer to acquire all of the capital stock of LifeWatch AG (SIX:LIFE).
The Research Division of BioTelemetry
BioTelemetry Research, (Cardiocore & VirtualScopics) is an industry leader in clinical trials testing services, monitoring, data, and scientific consulting. Our comprehensive offerings provide global clients with world-leading technology, data management, and consulting services, streamlining the clinical trials process, and ensuring optimal research performance.
Every day, BioTelemetry Research’s global clinical trials services team meets the demands of Phase I–IV studies for the world’s largest pharmaceutical organizations, specialty pharmaceutical firms, emerging biotechnology companies, and medical device manufacturers. Providing a full range of centralized clinical trials testing modalities for both safety and endpoint evaluation, our core offerings include:
- Global Cardiovascular Monitoring for Clinical Trials
- Advanced Imaging Services for Clinical Trials
- Respiratory Testing Alliance for Clinical Trials
Comprehensive Testing Services for Clinical Trials
Today as BioTelemetry Research, we are a member of the world’s largest cardiac data network — processing over 2 billion heartbeats a day, while supporting more than 20,000 sites and 30,000 devices monthly, as well as monitoring over 500,000 patients a year. In addition to industry-leading global cardiovascular monitoring, we have now expanded our clinical trial services in two important areas: advanced imaging services for oncology, neurologic, cardiac, and musculoskeletal imaging, and a global alliance for respiratory testing and clinical trials expertise.
Non-invasive Quantification of Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatisis (NASH) are emerging as the most prevalent causes of liver disease in Western countries. It is estimated that nearly 6 million Americans have NASH and nearly 600,000 have NASH-related cirrhosis. Download our whitepaper to learn more.
Join Svetlana Kolchinsky, Director of Project Operations, as she discusses how to manage multi-protocol programs and build efficiencies while being a good partner. Key topics include next level planning for risk management and project/program oversight, successful project delivery and lessons learned.